Abstract

The integration of Next-Generation Sequencing (NGS) with CRISPR technology represents a groundbreaking synergy in the field of drug discovery, offering unprecedented opportunities for accelerating the development of novel therapeutics. NGS provides comprehensive genomic data, enabling the identification of disease-associated genetic variations and potential therapeutic targets. When combined with CRISPR’s precise gene-editing capabilities, this powerful duo facilitates the functional validation of genetic targets and the creation of highly specific models of human diseases. This integrated approach enhances the efficiency of screening processes, allowing for the rapid identification and optimization of lead compounds. Additionally, it enables the discovery of new drug mechanisms and the development of personalized therapies by elucidating the genetic underpinnings of individual patient responses. As a result, the convergence of NGS and CRISPR is poised to transform the landscape of drug discovery, driving innovations that promise more effective and tailored treatments for a wide range of diseases.